Wysa, an artificial intelligence (AI) based digital companion for behavioural health, has been granted Breakthrough Device Designation by the Food and Drug Administration (FDA) for its AI-based digital mental health conversational agent for patients 18 years and older with a diagnosis of chronic musculoskeletal pain (defined as pain lasting longer than three months) and depression and anxiety.
Shutterstock
FDA Food and Drug Administration Health Product Standard Control System.
The device delivers cognitive behavioural therapy (CBT) via a smartphone-based conversational agent to reduce the symptoms of depression and anxiety, reduce pain interference, and improve physical function.
The designation follows an independent peer reviewed clinical trial, published in JMIR, that found Wysa to be effective for managing chronic pain and associated depression and anxiety, which was found to be more effective than standard orthopaedic care, and comparable to in-person psychological counselling.
Jo Aggarwal, CEO and co-founder of Wysa, said: “We’re thrilled to achieve this meaningful designation from the FDA and look forward to working closely with the Agency to continue development of AI-based cognitive behavioral therapy. Our mission is to help those in need of support with an always available platform, and during these challenging times it’s more crucial than ever to provide mental health options.”
The FDA Breakthrough Device program is designed to help accelerate the development and approval of medical devices and products that have the potential to provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. The FDA designation of Wysa’s platform will enable Wysa to efficiently communicate with FDA’s experts through various program options, facilitating the development of the product prior to the premarket review phase.
